Table 2.
Cross tables of responders vs. non-responders to initial and rechallenge treatments.
| a) ORR after initial ipilimumab/nivolumab treatment and rechallenge | ||||
|---|---|---|---|---|
| Response to rechallenge treatment | ||||
| No | Yes | Total | ||
| Response to initial treatment | No | 12 (34.4%) | 7 (20.0%) | 19 (54.3%) |
| Yes | 10 (28.6%) | 6 (17.1%) | 16 (45.7%) | |
| Total | 22 (62.9%) | 13 (37.1%) | 35 (100.0%) | |
| b) DCR after initial ipilimumab/nivolumab treatment and rechallenge | ||||
| Disease control after rechallenge treatment | ||||
| No | Yes | Total | ||
| Disease control after initial treatment | No | 9 (25.7%) | 5 (14.3%) | 14 (40.0%) |
| Yes | 11 (31.4%) | 10 (28.6%) | 21 (60.0%) | |
| Total | 20 (57.1%) | 15 (42.9%) | 35 (100.0%) | |
| c) ORR after initial ipilimumab monotherapy and rechallenge ipilimumab/nivolumab | ||||
| Response to rechallenge treatment | ||||
| No | Yes | Total | ||
| Response to initial treatment | No | 10 (33.0%) | 8 (26.7%) | 18 (60.0%) |
| Yes | 8 (26.7%) | 4 (13.3%) | 12 (40.0%) | |
| Total | 18 (60.0%) | 12 (40.0%) | 30 (100.0%) | |
| d) DCR after initial ipilimumab monotherapy and rechallenge ipilimumab/nivolumab | ||||
| Disease control after rechallenge treatment | ||||
| No | Yes | Total | ||
| Disease control after initial treatment | No | 6 (20.0%) | 3 (10.0%) | 9 (30.0%) |
| Yes | 10 (3.3%) | 11 (36.7%) | 21 (70.0%) | |
| Total | 16 (53.3%) | 14 (46.7%) | 30 (100.0%) | |